Quantum BioPharma Announces $750 Private Placement to Strengthen Capital Position

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has announced a non-brokered private placement of up to 30 Class A multiple voting shares at $25 per share, aiming to raise gross proceeds of up to $750. The biopharmaceutical company, which focuses on developing treatments for neurodegenerative, metabolic, and alcohol misuse disorders, received shareholder approval for this offering on September 26, 2025.

The private placement is expected to be fully subscribed by entities controlled by Zeeshan Saeed and Anthony Durkacz, two key figures associated with the company. This transaction will have significant implications for the company's governance structure, as the completion of the offering will increase voting rights attached to the Class A shares to 75.27%. This restoration brings the voting control nearly back to its original level when Quantum BioPharma went public in 2018, representing a substantial consolidation of insider control over corporate decisions.

According to the company's announcement, the proceeds from this financing will be allocated toward general working capital purposes. This capital infusion comes at a critical time for Quantum BioPharma as it continues to advance its pipeline of innovative treatments. The company maintains a diverse portfolio through its various subsidiaries and strategic investments, positioning itself in multiple therapeutic areas within the biopharmaceutical sector.

Through its wholly owned subsidiary Lucid Psycheceuticals Inc., Quantum BioPharma is focusing research and development efforts on its lead compound, Lucid-MS. This patented new chemical entity has demonstrated potential in preclinical models to prevent and reverse myelin degradation, which represents the underlying mechanism of multiple sclerosis. The successful development of Lucid-MS could address significant unmet medical needs in the neurodegenerative disease space, particularly for patients suffering from multiple sclerosis.

Quantum BioPharma's business strategy extends beyond its pharmaceutical development pipeline. The company invented unbuzzd(TM) and subsequently spun out its over-the-counter version to Unbuzzd Wellness Inc., formerly known as Celly Nutrition Corp. Quantum BioPharma retains ownership of 20.11% of Unbuzzd Wellness Inc. as of March 31, 2025, according to company disclosures. The agreement between the two entities includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum BioPharma total $250 million, after which the royalty decreases to 3% in perpetuity.

The company maintains full rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses, preserving its ability to leverage the unbuzzd(TM) technology in clinical applications. Additionally, Quantum BioPharma manages a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property, providing additional financial stability and diversification.

For investors seeking additional information about Quantum BioPharma's developments, the company maintains a newsroom at https://ibn.fm/QNTM where updates and announcements are regularly posted. The current private placement represents a strategic move to strengthen the company's financial position while consolidating voting control among existing insiders, potentially providing stability in leadership as the company advances its clinical development programs.